Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Withdrawn before enrolling · Phase 2

Conditions studied: Dedifferentiated Liposarcoma

In brief

The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.

Key facts

Study ID

NCT00969917

Run by

Infinity Pharmaceuticals, Inc.

People needed

0

Starts

2010-01-01

Expected to finish

2010-12-01

Last updated by the study team

2015-04-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age at the time of signing informed consent.
• Histologic diagnosis of dedifferentiated liposarcoma.
• Available archival pathology specimen or tissue sample from a new biopsy for confirmation of diagnosis by central pathology reading.
• At least one prior chemotherapy regimen for dedifferentiated liposarcoma.
• No more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. Note: Any number of non-chemotherapy regimens is permitted.
• Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST (version 1.1) with at least one measurable lesion.
• Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.
• Life expectancy ≥6 months.

You may not qualify if…

• Prior treatment with any heat shock protein 90 (Hsp90) inhibitor.
• Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease
• Patients with prior hepatic resections or hepatic-directed therapy
• Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to dosing.

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.